… As the RAS activity may be accelerated more in patients with severe diabetic nephropathy
than in patients with incipient nephropathy, we interpreted that valsartan substantially reduced …

… Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes,
valsartan … The purpose of this study was to evaluate the efficacy of valsartan combined …

… Our study indicates that aliskiren and/or valsartan protects against diabetic kidney disease
through multiple mechanisms, including decreasing podocyte injury, activation of profibrotic …

… , we examined the effect of aliskiren on type 2 diabetic nephropathy in detail and … diabetic
nephropathy. We obtained the evidence that aliskiren protected against diabetic nephropathy …

… role in the pathophysiology of diabetic nephropathy, with … mg/g or with diabetic kidney disease,
regardless of their blood … ARBs) for type 2 diabetes mellitus (T2D) nephropathy [ 5 ]. This …

… diabetes mellitus is the most frequent cause of kidney failure leading to dialysis.The first
manifestation of diabetic nephropathy … 10 years of their diagnosis of diabetes).Microalbuminuria …

… of its blood pressure lowering effects in the patients having either diabetic and non-diabetic
nephropathy. In this review, the studies investigating the renal effects of valsartan will be …

… Uninephrectomized db/db mice with diabetes developed overt nephropathy by 18 weeks of
… determine the effect of valsartan on the progression of established diabetic nephropathy in …

Aims To evaluate whether angiotensin‐converting enzyme (ACE) inhibitor and angiotensin II
receptor blocker (ARB) combination therapy is more nephroprotective than ACE inhibitor or …

… The additive effect of benazepril and valsartan on albuminuria, BP, and plasma … valsartan
alone. Therefore, the potential role of dual blockade depends on whether the observed effects …